Proteasome inhibitor MG132 was from Calbiochem. eIF4A1 inhibitor Rocaglamide A, alpha-glucosidase inhibitor Acarbose, protein disulfide isomerase (PDI) inhibitor 16F16, microsomal triglyceride transfer protein (MTTP) inhibitor lomitapaide and pan prolyl hydroxylase inhibitor ethyl 3,4-dihydroxybenzoate (EDHB) were from MilliporeSigma. Hsp70 inhibitors JG40 and JG345 were a gift from J. Gestwicki. Calmodulin inhibitor W7, Grp94 inhibitor PU-WS13, anti-fibrotic Nintedanib (BIBF 1120), HIF prolyl hydroxylase inhibitor Roxadustat (FG-4592) were from Cayman Chemicals. Diethyl-pythiDC was from AOBIOS.
Roxadustat fg 4592
Manufactured by Cayman Chemical
Sourced in Canada, United States
Roxadustat (FG-4592) is a small molecule compound developed by Cayman Chemical. It functions as an inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase, an enzyme involved in the regulation of the HIF pathway.
Automatically generated - may contain errors
Lab products found in correlation
Canagliflozin, by MedChemExpress (1 mentions)
Mycoalert mycoplasma detection kit, by Lonza (1 mentions)
H1299, by American Type Culture Collection (1 mentions)
H1975, by American Type Culture Collection (1 mentions)
Sk mes 1, by American Type Culture Collection (1 mentions)
Molidustat, by Cayman Chemical (1 mentions)
L name, by Merck Group (1 mentions)
Roxadustat, by Cayman Chemical (1 mentions)
3 protocols using roxadustat fg 4592
1
Inhibitors for Cellular Processes
2
Evaluating Anti-Cancer Drugs in Lung Cell Lines
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Human lung A549 (RRID:CVCL_0023), SK‐MES‐1 (RRID:CVCL_0630), H1299 (RRID:CVCL_0060), H1975 (RRID:CVCL_1511), and H460 (RRID:CVCL_0459) cancer cells were obtained from the American Type Culture Collection (ATCC: Manassa, VA). Cell lines were authenticated within the past 3 years using short tandem repeat DNA profiling and comparing the DNA sequences to the reference cell database, with an > 80% match being acceptable. Cells were assessed for mycoplasma contamination using the MycoAlert Mycoplasma Detection Kit (Lonza Group AG: Basel, Switzerland). Cell lines were cultured in DMEM (A549 and SK‐MES‐1), RPMI‐1640 (H1299 and H460) or ATCC‐modified RPMI‐1640 (H1975) with 10% FBS and 1% antibiotic‐antimycotic. All cells were maintained at 37 °C in a humidified 5% CO2 incubator. Cells were treated with canagliflozin (MedChemExpress LLC: Monmouth Junction, NJ) solubilized in dimethyl sulfoxide, cisplatin (Accord Healthcare Inc: Durham, NC), etoposide (Teva Canada Ltd: Toronto, Canada), radiation (6MV X‐rays as described [26 (link)]), Roxadustat (FG‐4592), BAY‐87‐2243, and IACS‐010759 (Cayman Chemical Company: Ann Arbor, MI).
3
Hypoxia-inducible factor prolyl hydroxylase inhibitors
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Roxadustat or molidustat were dissolved in vehicle [10% ethanol (70% grade) and 90% corn oil] and administered i.p.; Roxadustat (FG-4592, Cayman Chemical, Ann Arbor, MI, USA) at a dose of 1, 2, 10, 20 or 30 mg kg -1 ; molidustat (BAY 85-3934, Cayman Chemical, MI Ann Arbor, USA) at a dose of 1 or 10 mg kg -1 . Given its longer half-life, two doses of Roxadustat were administered 48 hours apart, with the second dose given 6 hours prior to tissue harvest or initiation of surgical procedures. Three doses of 1 mg kg -1 of molidustat were administered 24 hours apart and two doses of 10 mg kg -1 of molidustat were given 48 hours apart, with the final doses given 4 hours prior to tissue harvest or initiation of surgical procedures. L-NAME (Sigma-Aldrich, Steinheim, Germany) was dissolved in the same vehicle and was injected i.p. at a dose of 10 mg kg -1 on the day of surgery at the time of final HIF-PHI administration.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!